All News
#ACRbest Abstracts – Day 3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
Read ArticleUrinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read Article
Latest in Lupus Treatment at #ACR23
• Dr. Dall’Era & Dr. Furie
• Approach to Lupus Nephritis 🫘
• Treating Non-Renal SLE / Skin
#Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe
Mithu Maheswaranathan, MD ( View Tweet)
#Lupus #ACR23🦋
🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy
🔥Promising step towards future in revolutionizing Lupus T/t💡📑
💡Keeps efficacy of other vaccines intact!
Follow this thread showcasing other imp findings
#ACRambassador
1/2 https://t.co/aNFTmJiH0X
debaditya_roy ( View Tweet)
✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus:
BEFORE stepping-up with biologics, ask the key questions:
-Are you using proton-pump inhibitors (Drug-induced SCLE)
-Can I see your sunscreen?
-Can I see your hat?
-Are you smoking?
-Any HCQ blood levels? https://t.co/s73FqyjLOn
Laurent ARNAUD ( View Tweet)
Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China
20% met def’n- diff trajectories
37% flare
1/6 got damage in f/u
Some tapered Rx
How to identify safe to d/c Rx?
2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz
Janet Pope ( View Tweet)
#Lupus #nephritis - #inflammatory #fibrosis predicts #renal damage on #kidney #bx @ACRheum @RheumNow #ACR23 #2552 - similar in CRF from #Diabetes etc Biomarker is i-IFTA - same as other CRF diseases https://t.co/2LNn5Wn7rJ
Janet Pope ( View Tweet)
What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof
Janet Pope ( View Tweet)
After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe
Janet Pope ( View Tweet)
Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN
Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators
#ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33
Janet Pope ( View Tweet)
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. John Cush RheumNow ( View Tweet)
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope ( View Tweet)
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Md Yuzaiful Md Yusof ( View Tweet)
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm ( View Tweet)
#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J
Md Yuzaiful Md Yusof ( View Tweet)
And to continue
B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years
4000+ pts, 3% retinopathy over 5yrs
Predictors of HCQ retinopathy
-body weight
-sex
-age
-eGFR
-weight based dose mg/kg
-higher cumulative dose
Risk ranges 1% to >20%
@RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0
Aurelie Najm ( View Tweet)
#ACR23 Abstr# 2490 Data supporting aggressive early treatment in #SLE? Multicentre open label RCT in China showed low dose MMF + Pred 0.5mg/kg/d reduced severe flare & lupus nephritis cases vs HCQ + Pred in new onset SLE with high dsDNA but w/o major organ involvement @RheumNow https://t.co/oRlgCaOvXo
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr# 2487 How to reduce PBO response in #SLE trials? Try adding low dose GC as co-primary endpoint. Interim analysis of Phase 2 RCT: SRI-4 + sustained GC dose to ≤5mg/d or ≤BL from Wk16 to 28 was met more in Ianalumab (BAFF-R-i) vs PBO (44% vs 9%) @RheumNow https://t.co/JEnMWKilR6
Md Yuzaiful Md Yusof ( View Tweet)